Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Fixed-ratio combinations of basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1 RA) allow concomitant administration of two proven complementary injectable therapies for type 2 diabetes. This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy. RESEARCH DESIGN AND METHODS: LixiLan-G, a randomized, open-label, 26-week trial, compared switching to iGlarLixi versus continuing prior GLP-1 RA in patients with type 2 diabetes and HbA1c 7–9% (53–75 mmol/mol) taking maximum tolerated doses of a GLP-1 RA daily (60% on liraglutide once daily or exenatide twice daily) or weekly (40% on dulaglutide, exenatide extended release, or albiglutide) with metformin with or without pioglitazone and with or without sodium–glucose cotransporter 2 inhibitors. Adherence to randomized treatment was closely monitored throughout the study. RESULTS: iGlarLixi (n = 257) reduced HbA1c more than continued GLP-1 RA therapy (n = 257) from a baseline 7.8% (62 mmol/mol) in both to 6.7% (50 mmol/mol) and 7.4% (57 mmol/mol), respectively, at 26 weeks (least squares mean difference −0.6%; P < 0.0001). More iGlarLixi patients achieved HbA1c <7% (53 mmol/mol) (62% vs. 26%; P < 0.0001) and the composite of HbA1c <7% without documented symptomatic hypoglycemia (<54 mg/dL). Nausea and vomiting rates as well as numbers of documented symptomatic hypoglycemia events per patient-year were generally low but greater with iGlarLixi versus continued GLP-1 RA therapy. CONCLUSIONS: Switching to iGlarLixi improves glucose control for patients with type 2 diabetes insufficiently controlled on a maximum tolerated dose of a GLP-1 RA plus oral antihyperglycemic agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“The short-acting GLP-1 RA exerts insulin-stimulating and glucagon-suppressing effects while also slowing gastric emptying, resulting in blunted postprandial glucose excursions with a greater effect after the meal following the injection time and a residual glucose lowering effect after the next meal (5).”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
The International Hypoglycaemia Study Group (2017) · Diabetologia · doi:10.1007/s00125-016-4146-6 · Cited by 360
Rosenstock, J., Aronson, R., Grunberger, G., Hanefeld, M., Piatti, P., Serusclat, P., Cheng, X., Zhou, T., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0917 · Cited by 272
Self-citationAroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1495 · Cited by 260 · cited 1×
“iGlarLixi has been shown to be efficacious and well tolerated in patients with type 2 diabetes uncontrolled by oral antihyperglycemic drugs (OADs) in the LixiLan-O trial (6) or by basal insulin in the LixiLan-L trial (7).”
BackgroundSelf-citationSikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223
Linjawi, S., Bode, B. W., Chaykin, L. B., Courrèges, J.-P., Handelsman, Y., Lehmann, L. M., Mishra, A., & Simpson, R. W. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0218-3 · Cited by 136
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citationGlucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Indeed, these combinations provide a preferable alternative than simply increasing the insulin dose in subjects already exhibiting suboptimal glycemic responses to insulin [93,94] or those exhibiting insufficient responses to GLP-1R agonist therapy [95,96].”
Background2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 150
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 78
Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0393 · Cited by 63
“Both have been shown to provide improved glycemic control versus their individual components, along with weight-benefits compared with basal insulin and fewer gastrointestinal AEs compared with their GLP-1 RA component (17-22).”
BackgroundResultSelf-citationJain, A. B., Kanters, S., Khurana, R., Kissock, J., Severin, N., & Stafford, S. G. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00984-x · Cited by 47
Yang, W., Dong, X., Li, Q., Cheng, Z., Yuan, G., Liu, M. R., Xiao, J., Gu, S., Niemoeller, E., Chen, L., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14722 · Cited by 36
Self-citationMcCrimmon, R. J., Sifri, S. A., Emral, R., Mohan, V., Sauque‐Reyna, L., Trescolí, C., Lalic, N. M., Alvarez, A., Demil, N., Coudert, M., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14354 · Cited by 31
Self-citationPeralta, F. G., Al‐Ozairi, E., Jude, E. B., Li, X., & Rosenstock, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14365 · Cited by 29
Self-citationBala, C. G., Cerghizan, A., Mihai, B. M., Moise, M., & Guja, C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060852 · Cited by 26
Giorgino, F., Caruso, I., & Napoli, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108478 · Cited by 24
Kis, J. T., Nagy, G., & Kovács, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01128-5 · Cited by 24
Polonsky, W. H., Giorgino, F., Rosenstock, J., Whitmire, K., Lew, E., Coudert, M., Alvarez, A., Nicholls, C. J., & McCrimmon, R. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14822 · Cited by 22
Self-citationLandgraf, W., Bigot, G., Hess, S., Asplund, O., Groop, L., Ahlqvist, E., Käräjämäki, A., Owens, D. R., Frier, B. M., & Bolli, G. B. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110012 · Cited by 18
Jung, H. N., Cho, Y. K., Min, S. H., Kim, H. S., Kim, Y., Park, J., Lee, W. J., & Jung, C. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870722 · Cited by 17
Haluzík, M., Flekač, M., Lengyel, C., Taybani, Z. J., Guja, C., Mihai, B. M., Cerghizan, A., Martinka, E., Kovács, G., & Kempler, P. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00777-2 · Cited by 16
McCrimmon, R. J., Lamotte, M., Ramos, M., Alsaleh, A. J. O., Souhami, E., & Lew, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01156-1 · Cited by 16
Self-citationHome, P. D., Aroda, V. R., Blonde, L., Guyot, P., Shaunik, A., Fazeli, M. S., Goswami, H. H., Kalra, S., & Pourrahmat, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14136 · Cited by 14
Self-citationLisco, G., Tullio, A. D., Guastamacchia, E., & Triggiani, V. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200705211224 · Cited by 13
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzík, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 13
Haluzík, M., Taybani, Z. J., Araszkiewicz, A., Cerghizan, A., Mankovsky, B., Zuhdi, A., & Malecki, M. T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01610-w · Cited by 12
Ferrannini, E., Niemoeller, E., DEX, T. A., Servera, S., & Mari, A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14688 · Cited by 12
Self-citationHassanein, M. M., Malek, R., Sifri, S. A., Sahay, R. K., Büyükbeşe, M. A., Djaballah, K., Melas‐Melt, L., & Shaltout, I. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01642-2 · Cited by 12
Haluzík, M., Seufert, J., Guja, C., Bonnemaire, M., Bigot, G., Tournay, M., Kis, J. T., & Freemantle, N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01375-8 · Cited by 11
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.025 · Cited by 11
Horváth, L., Novodvorský, P., & Haluzík, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16645 · Cited by 10
Vargas‐Uricoechea, H., Frías, J. P., & Vargas-Sierra, H. D. (2023) · The Review of Diabetic Studies · doi:10.1900/rds.2023.19.14 · Cited by 10
Prato, S. D., Frías, J. P., Blonde, L., Aroda, V. R., Shehadeh, N., Saremi, A., DEX, T. A., Niemoeller, E., Souhami, E., Liu, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14068 · Cited by 10
Self-citationTranslating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
SKOLNIK, N., Prato, S. D., Blonde, L., Galstyan, G. R., & Rosenstock, J. (2021) · Advances in Therapy · doi:10.1007/s12325-020-01614-5 · Cited by 10
Self-citationChoi, J. H., Kang, S., Kim, S., Kim, W. J., Kim, J. M., Bae, J., Yun, J., Jeon, E. J., Kim, Y., Bae, J. H., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0978 · Cited by 9
Guo, X., Yang, W., Zhang, J., Dong, X., Liu, M. R., Gu, S., Lauand, F., Li, L., Huang, Q., Kang, L., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15074 · Cited by 9
Self-citationGuja, C., Giorgino, F., Blonde, L., Ali, A., Prázný, M., Meier, J. J., Souhami, E., LUBWAMA, R. N., Ji, C. F., & Rosenstock, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01180-1 · Cited by 9
Self-citationiGlarLixi for type 2 diabetes: a systematic review and meta-analysis
Liu, Y., Li, C., Li, X., Yang, J., Zheng, Y., Li, F., & Wang, X. (2024) · Endocrine · doi:10.1007/s12020-024-03868-3 · Cited by 8
Haluzík, M., Cypryk, K., Alvarez, A., Lauand, F., Bakıner, O., & Lim, S. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16276 · Cited by 8
Candido, R., Modugno, M., Larosa, M., Rossi, M. C., Nicolucci, A., Gabellieri, E., & the ENSURE Study Group (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01328-7 · Cited by 8
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Blonde, L., Rosenstock, J., Frías, J. P., Birkenfeld, A. L., Niemoeller, E., Souhami, E., Ji, C. F., Prato, S. D., & Aroda, V. R. (2021) · Diabetes Care · doi:10.2337/dc20-2023 · Cited by 8
Self-citationGuja, C., Kis, J. T., Haluzík, M., Bonnemaire, M., Bigot, G., Tournay, M., Freemantle, N., & Seufert, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15027 · Cited by 8
Novodvorský, P., Thieme, L., Laňková, I., Mráz, M., Taybani, Z. J., Bótyik, B., Stella, P., Vytasil, M., Lauand, F., Bonnemaire, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01582-x · Cited by 7
Cowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
Bailey, T. S., Gill, J., Merwyn Jones, S., Shenoy, L., Nicholls, C. J., & Westerbacka, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14739 · Cited by 7
Antsiferov, M. B., Demidov, N. A. D., Balberova, M. A., Safronova, T. I., Mishra, O. A. M., & Magomedova, S. G. (2022) · Diabetes Mellitus · doi:10.14341/dm12809 · Cited by 7
Suastika, K., Eliana, F., Kshanti, I. A., Mardianto, M., Mudjarnako, S. W., Natalia, N., Seno, H. N. H., Sibarani, R. P., Soewondo, P., Soelistijo, S. A., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s367153 · Cited by 7
Home, P., McCrimmon, R. J., Rosenstock, J., Blüher, M., Pegelow, K., Melas‐Melt, L., Djaballah, K., Giorgino, F., & the SoliMix trial investigators (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14907 · Cited by 7
Self-citationCowart, K., Gonzalez, R. V. L., & Carris, N. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14579 · Cited by 7
Jiang, Y., Liu, R., Xuan, J., Lin, S., Zheng, Q., & Pang, J. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01255-w · Cited by 7
Malik, R. A., Hwu, C., Jammah, A. A., Arteaga-Díaz, J. M., Djaballah, K., Pilorget, V., Alvarez, A., Vera, C., & Vikulova, O. K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15599 · Cited by 7
Effect of fixed-ratio insulin combinations on adherence in type 2 diabetes: Systematic review
Elamin, M., & Barnish, M. S. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103072 · Cited by 6
Frías, J. P., Ratzki‐Leewing, A. A., DEX, T. A., Meneghini, L., Rodrigues, A., & Shah, V. N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16214 · Cited by 6
Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16616 · Cited by 6
Kroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
Malik, R. A., Anderson, J., Russo, G. T., Amani, M. E. A., Adaş, M., Alvarez, A., Lauand, F., Li, X., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16591 · Cited by 5
Fixed ratio combinations GLP-1RA and basal insulin: literature review
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Strygin, A. V., Gorbunova, Y. V., Волотова, Е. В., Robertus, A. I., Макаренко, И. Е., Saparova, V. B., Васильевич, Д. Р., et al. (2024) · Problems of Endocrinology · doi:10.14341/probl13312 · Cited by 5
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.03.023 · Cited by 5
Seufert, J., Freemantle, N., Guja, C., Haluzík, M., Tournay, M., Vera, C., Bonnemaire, M., & Kis, J. T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15609 · Cited by 5
Haluzík, M., Al‐Sofiani, M. E., CHENG, A. Y. Y., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15811 · Cited by 4
Self-citationKis, J. T., Seufert, J., Haluzík, M., Bonnemaire, M., Vera, C., Tournay, M., Freemantle, N., & Guja, C. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01644-0 · Cited by 4
Jammah, A. A., Roushdy, N., Gamil, M., Diab, N. A., Abdelmonaem, N., Safarini, S., Gadallah, M., Zaid, N. A., Shihadeh, Y., Saeed, M., et al. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100164 · Cited by 3
Open questions on basal insulin therapy in T2D: a Delphi consensus
Delphi Board, Alberto, A., Roberto, A., Angelo, A., Baggiore, C., cesare, B., Bonadonna, R. C., Giuseppe, C. S. M., Andrea, D. P., Lorenzo, D. C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02285-2 · Cited by 3
Xie, P., He, X., Gao, X., Shuai, M., Schmider, W., Jiang, A., Yang, N., & Shi, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01434-0 · Cited by 2
Kwiendacz, H., Nabrdalik, K., Czupryniak, L., Klupa, T., Malecki, M. T., Myśliwiec, M., Strojek, K., & Gumprecht, J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02567-1 · Cited by 2
Noh, J. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.127 · Cited by 2
Munshi, M. N., Ritzel, R. A., Jude, E. B., DEX, T. A., Melas‐Melt, L., & Rosenstock, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15377 · Cited by 2
Self-citationGiorgino, F., Guja, C., Aydın, H., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111604 · Cited by 2
Self-citationSafety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico
Rosas-Guzmán, J., Navarro‐Lara, A., Sañudo‐Maury, M. E., Anguiano, L., & Sauque‐Reyna, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16357 · Cited by 2
Fonseca, V. A., Sood, M., & Galindo, R. J. (2021) · Clinical Diabetes · doi:10.2337/cd20-0121 · Cited by 2
Yang, W., Guo, X., Lauand, F., Li, L., Fang, H., Du, Q., & Kang, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15414 · Cited by 1
Gu, W., Wu, X., Zhang, M., Wang, X., Du, Q., Kang, L., Lauand, F., Alvarez, A., & Mu, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70181 · Cited by 1
Yu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70192 · Cited by 1
Rosenstock, J., Blonde, L., Aroda, V. R., Frías, J. P., Souhami, E., Ji, C. F., Niemoeller, E., & Prato, S. D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14345 · Cited by 1
Self-citationGautier, T., Silwal, R., Saremi, A., Boss, A., & Breton, M. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211015671 · Cited by 1
Munshi, M. N., Ritzel, R. A., HRAMIAK, I. M., Galstyan, G. R., Souhami, E., DEX, T. A., Melas‐Melt, L., & Rosenstock, J. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155429 · Cited by 1
Self-citationVikulova, O. K., Atanesyan, R. A., Мовсесян, С. Д., Касаткина, Ю. П., Перевязка, А. А., Zaitseva, E. L., Kharakhulakh, M. I., Andreeva, N. V., Krivosheyeva, I. A., Vorobyev, S. V., et al. (2024) · Diabetes Mellitus · doi:10.14341/dm13236 · Cited by 1
Home, P. D., Lauand, F., Djaballah, K., Li, X., Hafidh, K., Mehta, R., Faraoun, K., Anaforoğlu, İ., Serafini, P. R., & Pourrahmat, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16360 · Cited by 1
Zhang, S., Gu, Y., Cheng, Y., Hu, Y., Li, B., Alvarez, A., Lauand, F., Melas‐Melt, L., Zhang, M., Jiang, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71057 · Cited by 1
Antsiferov, M. B., Koteshkova, O. M. K., Духарева, О. В., Александрович, Д. Н., & Ermakova, E. A. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-26-38-42
Antsiferov, M. B., Demidov, N. A. D., Balberova, M. A., Safronova, T. I., & Mishra, O. A. M. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-3-12-19
Delphi, B. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.4.3
Folyamatos glükózmonitorozás glargin inzulin + lixiszenatid fix kombináció használatakor
Hermányi, Z., Jankovec, Z., Maule, P., Taybani, Z. J., Veselá, A., Bonnemaire, M., & Fülöp, R. (2024) · Lege Artis Medicinae · doi:10.33616/lam.34.0417
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Huang, C., Yang, S. N., Cheng, C.-P., Lin, C., Lee, Y. S., & Chen, H.-S. (2026) · Diabetic Medicine · doi:10.1111/dme.70275
Assaad-Khalil, S. H., Abdelaaty, T., Rizk, M. N., Megallaa, M. H. Z., Elsayed, M., Wafa, A. M., Ismail, A., Sharafeldeen, B., & Amin, N. G. (2026) · Diabetology · doi:10.3390/diabetology7050090
Urhan, E. (2026) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.1840385
Li, X., Wang, J., Liu, T., Alvarez, A., Lauand, F., Melas‐Melt, L., Kang, L., Du, Q., & Liu, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70902
Ni, J., Lu, J., Gao, F., Li, M., Zhang, M., Du, Q., Kang, L., Peng, D., & Zhou, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71036
Luo, Y., Xia, J., Yao, X., Jahed, S. A., Bee, Y. M., Chen, L., Chan, S. P., Deerochanawong, C., Alice Pik Shan, K. O. N. G., Nguyen, K. T., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113474
Giorgino, F., Haluzík, M., Alvarez, A., Lauand, F., Assaad-Khalil, S. H., Thacker, H. P., Klupa, T., Deyneli, O., & Rosenstock, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71436
Self-citationKamrul-Hasan, A. B. M., Mondal, S., Nagendra, L., Khalil, I., Dutta, D., & Pappachan, J. M. (2026) · Endocrine · doi:10.1007/s12020-026-04857-4
Jung, H. N., Cho, Y. K., Min, S. H., Kim, H. S., Kim, Y.-J., Park, J.-Y., Lee, W. J., & Jung, C. H. (2022) · doi:10.3389/fendo.2022.870722.s001
Metadata
- Authors
- Blonde, L., Rosenstock, J., Del Prato, S., Henry, R., Shehadeh, N., Frias, J., Niemoeller, E., Souhami, E., Ji, C., & Aroda, V. R.
- Affiliations
- Ochsner Medical Center (US)
- Dallas Diabetes Research Center (US)
- University of Pisa School of Medicine, Pisa, Italy
- University of California San Diego (US)
- Rambam Health Care Campus (IL)
- National Research Institute, Los Angeles, CA
- Sanofi (Germany) (DE)
- Sanofi (France) (FR)
- Sanofi (China) (CN)
- Brigham and Women's Hospital (US)
- Corresponding author
- Blonde, Lawrence
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-17
- Volume
- 42
- Issue
- 11
- Pages
- 2108-2116
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2973598479
- Cited by
- 85
- References
- 13
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 18 · 2023: 12 · 2022: 14 · 2021: 14 · 2020: 7
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, iGlarLixi, insulin glargine, lixisenatide, GLP-1 receptor agonists, treatment switching, glycemic control, HbA1c, symptomatic hypoglycemia, nausea and vomiting, liraglutide, dulaglutide, exenatide
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Insulin Glargine, Sodium-Glucose Transporter 2 Inhibitors, Pioglitazone, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Combinations, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Peptides, Recombinant Fusion Proteins, Treatment Outcome, Drug Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.